These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16338614)

  • 1. Use of DMPA by adolescents.
    Gold MA; Hertweck SP; Lara-Torre E
    J Pediatr Adolesc Gynecol; 2005 Dec; 18(6):435-7. PubMed ID: 16338614
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
    Modesto W; Bahamondes MV; Bahamondes L
    J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and DMPA.
    Westhoff C
    J Reprod Med; 2002 Sep; 47(9 Suppl):795-9. PubMed ID: 12380409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate.
    Lange HL; Manos BE; Gothard MD; Rogers LK; Bonny AE
    J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):169-175. PubMed ID: 27789350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone loss in adolescents using Depo-Provera.
    Kass-Wolff JH
    J Soc Pediatr Nurs; 2001; 6(1):21-31. PubMed ID: 11288500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable hormone contraception and bone density: results from a prospective study.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Epidemiology; 2002 Sep; 13(5):581-7. PubMed ID: 12192229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age.
    Gai L; Zhang J; Zhang H; Gai P; Zhou L; Liu Y
    Contraception; 2011 Mar; 83(3):218-22. PubMed ID: 21310282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls.
    Cromer BA; Stager M; Bonny A; Lazebnik R; Rome E; Ziegler J; Debanne SM
    J Adolesc Health; 2004 Dec; 35(6):434-41. PubMed ID: 15581522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
    Clark MK; Sowers MR; Nichols S; Levy B
    Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%.
    Harel Z; Wolter K; Gold MA; Cromer B; Stager M; Johnson CC; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Burkman R; Nelson A; Marshall S; Bachrach LK
    Contraception; 2010 Dec; 82(6):503-12. PubMed ID: 21074012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in women of a low socioeconomic level using DMPA for contraception in rural Upper Egypt.
    Hussein M; Mahran DG; Farouk OA; El-Assal MA; Fathallah MM; Romih MS
    Int J Gynaecol Obstet; 2010 Jul; 110(1):31-4. PubMed ID: 20347086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2008 Sep; 112(3):727-30. PubMed ID: 18757687
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
    Kaunitz AM; Arias R; McClung M
    Contraception; 2008 Feb; 77(2):67-76. PubMed ID: 18226668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depo-Provera and bone density.
    Gbolade BA
    J Fam Plann Reprod Health Care; 2002 Jan; 28(1):7-11; quiz 11, 50. PubMed ID: 16259806
    [No Abstract]   [Full Text] [Related]  

  • 18. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 19. DMPA and bone density.
    BMJ; 1991 Aug; 303(6800):467-8. PubMed ID: 1833007
    [No Abstract]   [Full Text] [Related]  

  • 20. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
    Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
    J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.